ZVS101e in Patients With Bietti's Crystalline Dystrophy

Inclusion Criteria: 1. Voluntarily participate in the research and sign the informed consent form, and be willing to complete the entire process according to the protocol requirements; 2. Clinically diagnosed with Bietti's Crystalline Dystrophy (BCD), age ≥ 18 years; 3. Confirmed by genetic testing to carry homozygous or compound heterozygous mutations in CYP4V2, and not complicated with other ophthalmic genetic diseases; 4. Target eye BCVA ≤ 60 ETDRS letters. Exclusion Criteria: Subjects will be excluded if they meet any 1 of the following exclusion criteria: 1. The target eye currently has or has a history of macular lesions; suffers from ocular diseases that may hinder surgery or interfere with the interpretation of study endpoints; 2. The target eye has previously undergone retinal reattachment surgery, vitrectomy, or any intraocular surgery within 3 months before enrollment; 3. Within 1 month before enrollment, suffered from viral infectious diseases that may affect the evaluation of the efficacy and safety of the investigational drug, or received antiviral vaccines; 4. The target eye has previously received gene therapy or stem cell therapy for BCD or other ocular diseases; 5. Known allergy to the drugs planned for use in the study; 6. The laboratory abnormalities are considered clinically significant; 7. Pregnant or lactating females.